Quince Therapeutics (QNCX) – Investment Analysts’ Weekly Ratings Changes

Several analysts have recently updated their ratings and price targets for Quince Therapeutics (NASDAQ: QNCX):

• 12/29/2025 – Quince Therapeutics had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/22/2025 – Quince Therapeutics had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/15/2025 – Quince Therapeutics had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/15/2025 – Quince Therapeutics had its price target raised by analysts at D. Boral Capital from $4.00 to $5.00. They now have a “buy” rating on the stock.
• 12/8/2025 – Quince Therapeutics had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/1/2025 – Quince Therapeutics had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/24/2025 – Quince Therapeutics had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/13/2025 – Quince Therapeutics had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $4.00 price target on the stock.

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions.